[ad_1]
The world’s leading pharmaceutical companies and equipment manufacturers were present, and the number of “big names” was the highest three times.
Hot medical exhibition area opens up new opportunities in China
Two showrooms with an exhibition area of more than 60,000 square meters, the world’s leading pharmaceutical companies and equipment manufacturers attended the exhibition, and the number of “big names” was the highest in three sessions. At the 3rd China International Import Expo (hereinafter “CIIE”), medical care has become a hot area of international cooperation.
With economic development and improvements in consumption, China’s medical and healthcare market is growing rapidly. At the same time, China continues to expand its market opening and will steadfastly continue to relax market access, strengthen intellectual property protection, safeguard the legitimate rights and interests of foreign-funded companies, and make it clear that the Chinese market is will become a global market. This has further stimulated the enthusiasm of foreign companies for the Chinese market. The reporter learned on the CIIE site that exhibitors have expressed optimism about the potential of China’s medical and healthcare industry, especially the prospects for the field of technology-driven smart medicine, and opportunities for cooperation and exchange. offered by the CIIE, and will further increase their exposure to the Chinese market. Design.
All the “big names” in the industry are there
The planned exhibition area of the medical exhibition area is 60,000 square meters, and the actual exhibition area far exceeds the planned area. There are nearly 340 exhibitors, the world’s top 500 companies and more than 70 leading companies, the world’s top ten pharmaceutical companies, and the world’s top 14 medical device companies. Go to all appointments. This year’s CIIE medical exhibition area is packed and has become the center of attention.
These include high-precision medical equipment and advanced medical service solutions, including home medical equipment, drugs for permanent chronic diseases, and nutrition and health products, covering all medical and health aspects.
The reporter saw in the showroom that the “world’s smallest pacemaker,” Medtronic Micra’s dual-chamber leadless pacing system, is as compact as the size of a capsule. The booth staff presented that in 2019 the first generation of Micra officially entered the country. The second generation of this product, which weighs only 2 grams, was exhibited at the CIIE, but the proportion of people adapted to it has increased 30%. Expand to 70%.
At the Novo Nordisk booth, which focuses on the treatment of diabetes, in addition to 14 innovative drugs and 9 innovative injection devices that have been included in China, its innovative insulin degludec and liraglutide, GLP-1 analog also appeared series of global innovations in the field of diabetes, such as single needle mixed products.
Omron from Japan has brought an integrated ECG blood pressure monitor. This is reportedly the world’s first sphygmomanometer equipped with an EKG electrocardiogram. It can monitor blood pressure and atrial fibrillation, two important indicators related to stroke. It also enables patients and physicians to be closely connected via the Internet and applications to help Physicians complete diagnoses, monitor diseases, and improve treatment plans more efficiently and accurately.
In addition, health products have also become a hot topic. MEBO International introduced its flagship products, such as an enhanced version of GI REGENERATE containing a variety of regenerated nutrients and natural ingredients, and an enhanced version of Glymate, a dietary supplement for blood sugar balancing.
A larger market space opens
The popularity of the exhibition is due to market expectations. The “2020 China Shared Health Opportunities White Paper” published in the “Fourth Forum of the Industrial Revolution and Smart Healthcare” supporting the CIIE shows that in 2019, China’s total health spending reached 6 , 5 trillion yuan, which represents 6.58% of GDP. . The overall scale of China’s healthcare industry is second only to the United States, ranking second in the world.
The “White Paper” also noted that the development of China’s healthcare market is still in an early stage and has great growth potential. China’s total health spending accounted for about 6% of GDP, while global spending on health care products and services accounted for 9.88% of GDP in 2017, and in 2018, health spending of the countries of the OECD represented an average of 8.8% of GDP. Especially in developed countries like the United States, Japan and Canada, the share of health spending exceeds 10% of GDP. This shows that China’s healthcare market still has broad development prospects.
The “White Paper” also shows that as people’s requirements for quality of life increase, the demand for traditional medical treatment has gradually shifted towards health care, management and prevention. Between 2010 and 2015, China’s per capita health spending increased by more than 10%, making it one of the few emerging industries to outpace GDP growth. The health services industry has also shown new formats, continuously integrating with industries such as care for the elderly, tourism, Internet, fitness and leisure, food and sports, giving rise to new industries, formats and models. of health.
According to statistics from the Tou Leopard Research Institute, the market size of China’s health management services industry increased from 105.43 billion yuan in 2014 to 248.11 billion yuan in 2018, with a 23.9% compound annual growth rate.
At the same time, China’s fast-growing medical and healthcare market is still expanding and opening up. Deputy Trade Minister Ren Hongbin stated at the aforementioned forum that we want to turn the Chinese market into a global market, a market for all and a shared market. It is foreseeable that the potential of the Chinese medical market will be further unleashed in the future.
Smart health takes center stage
It is worth mentioning that in the field of medical and health cooperation, the prospect of smart health care has attracted much attention. Ren Hongbin said that China’s smart medical market is expanding rapidly. According to statistics from relevant agencies, China has become the world’s third-largest smart medical market after the United States and Japan. With the development of China’s economy and society and the improvement of residents’ incomes, China’s smart medical market will continue to expand.
Related policies are also accelerating. Qi Guixin, a first-level inspector of the Department of Planning, Development and Informatization of the National Health Commission, said that during the period of the “XIV Five-Year Plan”, opportunities and challenges of health informatization work coexist. We urgently need to adhere to the problem-oriented and goal-oriented approach to continue to improve infrastructure, Little by little to open the artery of information for the development of the health industry.
Qi Guixin said it will promote the further development of the digital economy in the health field, vigorously develop new business formats such as Internet health care, smart health care, digital health management and smart Chinese medicine, accelerate the formation of a market for medical data and will promote smart health as a new growth point. .
The combination of market growth and policy support has also further fueled the enthusiasm of multinational companies to expand investment in the Chinese market. Song Weiqun, global senior vice president and president of Johnson & Johnson, China, said China’s innovation in artificial intelligence, 3D printing, 5G, surgical robots and other fields is developing rapidly. With the accelerated integration of cutting-edge technology and medical fields, smart medicine has a bright future in China. China is increasingly becoming the world’s leading innovation engine. “We hope that in the future, more China-originated innovations can be promoted globally to better serve the health needs of patients and consumers,” said Song Weiqun.
Zhang Jun, President of Boston Scientific Greater China, said that with the help of the CIIE platform, Boston Scientific will further cultivate the Chinese market and grow together with local partners through a diversified and innovative cooperation model. “We will continue to actively promote open innovation and deep cooperation with local medical companies, promote the collapse of high-quality medical resources, improve the timeliness and accessibility of primary care, and help a ‘healthy China.’
As a company focused on the development of regenerative life sciences, Xu Peng, Chairman of the Board of the MEBO Group, said that the company’s presence in the three CIIEs is to assess the development prospects of the Chinese healthcare market and the advanced development provided by the CIIE platform. Technology and product exchange opportunities. In the future, it will also accelerate the technological upgrade and innovation of renewable products, follow the development trend of digitization, networks and intelligence, and open new models and new channels, such as international cross-border e-commerce. (Reporter Wang Wenbo)
